CCM
PACB icon

Chiron Capital Management’s Pacific Biosciences PACB Stock Holding History

Chiron Capital Management’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-2,000
Closed -$20K – 338
2020
Q3 		$20K Buy
+2,000
New +$11.5K 0.02% 226

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
SM
SB Management Abu Dhabi, United Arab Emirates $516M AUM 40.71% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Chiron Capital Management's PACB Position: Q4 2020 in Review

Chiron Capital Management sold out of Pacific Biosciences (PACB) in Q4 2020, closing a stake of 2,000 shares — an estimated $20K sold.

Chiron Capital Management first reported a position in PACB in Q3 2020 and held it in 1 quarter. The position peaked at $20K in Q3 2020. 210 funds tracked by Wall St. Rank hold PACB as of Q4 2020.

  • Chiron Capital Management reported no remaining Pacific Biosciences position as of Q4 2020 after selling out during the quarter.
  • Chiron Capital Management sold 2,000 Pacific Biosciences shares in Q4 2020, an estimated $20K.
  • Chiron Capital Management first reported a position in Pacific Biosciences in Q3 2020 and held it in 1 quarter.
  • Chiron Capital Management's Pacific Biosciences position peaked at $20K in Q3 2020.
  • 210 funds tracked by Wall St. Rank held Pacific Biosciences as of Q4 2020.

Based on Chiron Capital Management's 13F filing for Q4 2020, filed 5 Mar 2021.